Le Lézard
Classified in: Health
Subjects: CHI, SVY, AVO

Several In Utero Fluoride/IQ Studies Should Provoke A Nation-Wide Fluoridation Moratorium


NEW YORK, Aug. 30, 2019 /PRNewswire/ -- Critics of the fluoride-IQ study published this month in JAMA Pediatrics claimed it needed replication. However, the Canadian study by Green (2019) was already a replication of another U.S. government-funded study published in 2017 by Bashash which found similar effects, reports the Fluoride Action Network (FAN).

Both were Mother-Offspring studies that used urinary fluoride levels during pregnancy to assess cognition in the paired offspring. 

Both studies have shown a strong relationship between maternal exposure to fluoride and lowered IQ in offspring. Each revealed that the fetal stage appears to be the most vulnerable time period for fluoride's neurotoxicity.

Actually, FAN points out that there have been five studies that have found this relationship between maternal exposure and lowered IQ in children (see listing below). However, the Canadian study is the first to compare fluoridated vs non-fluoridated cities. The pregnant women in Canada with higher urinary fluoride levels had offspring with lower IQs and were from the fluoridated cities.

Paul Connett, PhD, FAN Executive Director, says, "For years promoters of fluoridation have argued that there is no harm from fluoridation; these and other studies indicate that there is potential harm and it is serious. It is unconscionable to continue fluoridation until this is resolved. For those who doubt the current findings more studies can be done once a moratorium on fluoridation is in place. To do otherwise is to condone a human experiment on millions of children."

Connett adds, "To ignore brain health and continue fluoridation in name of dental health is a huge disservice to the children of this country. FAN argues that there are more effective programs to reduce dental inequities (eg, 'Childsmile' in Scotland) and communities can easily implement them."

The Mother-Offspring studies, listed below, can be accessed at http://fluoridealert.org/issues/moms2b/mother-offspring-studies/

Green (2019). Largest study with 512 mother-offspring. Lower IQ in children 3- 4 years of age.

Bashash (2017). Longest study. 299 mother-offspring pairs in Mexico. Lower IQ in children 4 and 6-12 years of age.

Thomas (2018). 401 mother-offspring pairs in Mexico. Lower IQ in children 1-3 years of age Only the abstract has been published.

Valdez Jiménez (2017). Lower IQ between the ages of 3-15 months with 65 mother-offspring pairs in Mexico.

Li (2004). Significant differences in the neonatal behavioral neurological assessment score in 91 offspring aged 1-3 days old.

SOURCE Fluoride Action Network


These press releases may also interest you

at 03:35
NodThera, a clinical stage biotechnology company developing a new class of medicines that inhibit the NLRP3 inflammasome to treat diseases driven by chronic inflammation, today announced that it has secured $55 million (£44 million) in a Series B...

at 03:30
Novo Ventures, part of Novo Holdings, today announced that it has led the $55 million (£44 million) Series B financing in NodThera, a UK and US based clinical stage biotechnology company developing a new class of medicines to treat diseases driven by...

at 03:10
AgraFlora Organics International Inc.  ("AgraFlora" or the "Company") is pleased to announce that on May 28, 2020, its subsidiary The Edibles and Infusions Corporation ("EIC") submitted its Site Evidence Package (the "Evidence Package") to Health...

at 03:00
Avectas today announced that it has entered into a collaborative agreement with The Simon Laboratory at UC Davis, California, USA (UCD) to engage in the characterisation of cells engineered with Avectas' proprietary, non-viral SOLUPOREtm cell...

at 03:00
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announced the publication of new clinical evidence further validating the exceptional performance of its proprietary OXINIUM - Oxidized Zirconium - on XLPE (highly...

at 03:00
Shorla Pharma Limited ('Shorla'), an Irish specialty pharmaceutical company, has today announced the completion of a Series A investment of $8.3 million. The financing was led by Seroba Life Sciences ('Seroba'), a European Venture Capital firm...



News published on 30 august 2019 at 09:32 and distributed by: